Azerbaijan vs Belgium: HIV/AIDS deaths averted by antiretroviral therapy
Azerbaijan
607.42 deaths
in 2024
Belgium
636.61 deaths
in 2024
Azerbaijan rank
87th
Belgium rank
85th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Azerbaijan
- Belgium
How they compare
Belgium currently reports 636.61 deaths against 607.42 deaths in Azerbaijan, a difference of 29.19 deaths.
Across all 35 years both countries report, Belgium has been ahead every year.
Azerbaijan ranks 87th and Belgium ranks 85th of 157 countries.
Belgium has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Azerbaijan | Belgium | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 99.54 deaths | 99.54 deaths | Belgium |
| 2000s | 12.14 deaths | 355.19 deaths | 343.05 deaths | Belgium |
| 2010s | 273.78 deaths | 595.22 deaths | 321.44 deaths | Belgium |
| 2020s | 561.31 deaths | 650.64 deaths | 89.33 deaths | Belgium |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Azerbaijan or Belgium?
- Belgium, at 636.61 deaths against 607.42 deaths in Azerbaijan as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Azerbaijan and Belgium?
- 29.19 deaths, with Belgium ahead.
- How many years of comparable data are there for Azerbaijan and Belgium?
- 35 years are reported by both, from 1990 to 2024.
- How do Azerbaijan and Belgium rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Azerbaijan ranks 87th and Belgium ranks 85th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.